November 21, 2016 - By Marguerite Chambers · 0 Comments
The stock of Vtv Therapeutics Class A (NASDAQ:VTVT) registered a decrease of 1.94% in short interest. VTVT’s total short interest was 232,300 shares in November as published by FINRA. Its down 1.94% from 236,900 shares, reported previously. With 32,600 shares average volume, it will take short sellers 7 days to cover their VTVT’s short positions. The short interest to Vtv Therapeutics Class A’s float is 3.22%. The stock closed at $5.84 during the last session. It is down 3.79% since April 19, 2016 and is downtrending. It has underperformed by 7.65% the S&P500.
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $195.30 million. The Firm is engaged in the discovery and development of orally administered small molecule drug candidates. It currently has negative earnings. The Company’s drug candidate for the treatment of Alzheimer’s disease is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
Out of 3 analysts covering vTv Therapeutics Inc (NASDAQ:VTVT), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. vTv Therapeutics Inc has been the topic of 3 analyst reports since August 24, 2015 according to StockzIntelligence Inc. The stock of vTv Therapeutics Inc (NASDAQ:VTVT) has “Overweight” rating given on Monday, August 24 by Piper Jaffray. Stifel Nicolaus initiated it with “Buy” rating and $17 target price in Monday, August 24 report. The firm has “Buy” rating by Canaccord Genuity given on Friday, September 4.
vTv Therapeutics Inc., incorporated on April 02, 2015, is a clinical-stage biopharmaceutical company. The Firm is engaged in the discovery and development of orally administered small molecule drug candidates. The Company’s drug candidate for the treatment of Alzheimer’s disease (AD), azeliragon (TTP488), is an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial (the STEADFAST Study) under a Food and Drug Administration (FDA) agreed Special Protocol Assessment (SPA). The Company’s type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial (the AGATA Study), and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
More important recent vTv Therapeutics Inc (NASDAQ:VTVT) news were published by: Businesswire.com which released: “vTv Therapeutics Inc. Announces Pricing of Initial Public Offering” on July 30, 2015, also Businesswire.com published article titled: “vTv Therapeutics to Participate in Upcoming Mizuho, Stifel and Piper Jaffray …”, Streetinsider.com published: “vTv Therapeutics (VTVT) to Present New Small Molecule Drug Candidate Data as …” on November 16, 2016. More interesting news about vTv Therapeutics Inc (NASDAQ:VTVT) was released by: Businesswire.com and their article: “vTv Therapeutics Reports Third Quarter Financial and Operational Results and …” with publication date: November 02, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Marguerite Chambers